Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452264 | 0.96 | TDP1 (0.38) | TDP1LMNAALDH1A1PTGS2CTSL | |
| SCHEMBL30497044 | 0.91 | TDP1 (0.38) | TDP1LMNAALDH1A1CTSLCTSB | |
| Stearic Acid SCHEMBL15049028 | 0.86 | TDP1 (0.43) | TDP1LMNAALDH1A1CTSLCTSB | |
| SCHEMBL62157 | 0.86 | CTSK (0.44) | TDP1LMNAALDH1A1CTSLCTSB | |
| SCHEMBL14698302 | 0.86 | CTSK (0.44) | TDP1LMNAALDH1A1CTSLCTSB | |
| SCHEMBL19717782 | 0.85 | CTSK (0.42) | TDP1LMNAALDH1A1CTSLCTSB | |
| SCHEMBL30779116 | 0.84 | TDP1 (0.44) | TDP1LMNAALDH1A1PTGS2CES2 | |
| Glycine SCHEMBL4305400 | 0.81 | CTSK (0.40) | TDP1LMNAALDH1A1CTSLCTSB | |
| Cinnamic Acid SCHEMBL14166230 | 0.80 | EGFR (0.44) | LMNAALDH1A1CTSLCTSBCTSK | |
| SCHEMBL38663795 | 0.80 | TDP1 (0.50) | TDP1LMNAPTGS2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120055840-A1 | COMPOSITIONS FOR DYEING KERATIN-CONTAINING FIBERS | KELLY VAN GOGH, INC. | 2012-03-08 | — | — | US | claimed |
| US-8052762-B1 | Compositions for dyeing keratin-containing fibers | Kelly Van Gogh, LLC (US) | 2011-11-08 | — | — | US | claimed |
| EP-4079286-B1 | SUNSCREEN COSMETIC | SHISEIDO CO LTD (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20250332084-A1 | PEPTIDE COMPOSITION AND RESPECTIVE USES | UNIVERSIDADE DO MINHO (PT) | 2025-10-30 | — | — | US | disclosed |
| US-20250312260-A1 | COMPOSITION FOR IMPROVING HAIR HEALTH | K18, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4007561-B1 | PREVENTION AND REDUCTION OF CORNIFICATION DISORDERS AND RELATED COSMETIC AGENTS | MERCK PATENT GMBH (DE) | 2025-08-27 | — | — | EP | disclosed |
| US-20250255791-A1 | POWDER COSMETIC CONTAINING ULTRAVIOLET WAVELENGTH-CONVERTING SUBSTANCE, AND METHOD FOR PRODUCING SAME | SHISEIDO COMPANY, LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12383484-B2 | Peptide composition and respective uses | UNIVERSIDADE DO MINHO (PT) | 2025-08-12 | — | — | US | disclosed |
| US-12357556-B2 | Composition for improving hair health | K18, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3623013-B1 | A COMPOSITION FOR IMPROVING HAIR HEALTH | K18 INC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12115242-B2 | Peptide composition and respective uses | UNIVERSIDADE DO MINHO (PT) | 2024-10-15 | — | — | US | disclosed |
| WO-2011143254-A2 | PERSONAL CARE FORMULATIONS CONTAINING ALKYL KETAL ESTERS AND METHODS OF MANUFACTURE | SEGETIS, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-8052762-B1 | Compositions for dyeing keratin-containing fibers | Kelly Van Gogh, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2361608-A1 | O/W EMULSION COMPOSITION | Shiseido Company, Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20110206628-A1 | O/W Emulsified Composition | SHISEIDO COMPANY, LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110206627-A1 | O/W Emulsified Composition | SHISEIDO COMPANY, LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2351551-A1 | O/W EMULSION COMPOSITION | Shiseido Company, Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7186687-B2 | Compositions and methods for treatment of Psoriasis | PROCYTE CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | RBP1, RBP4, SOD1 | TDP1 383/4885LMNA 215/4885ALDH1A1 361/4885 |
| US-20120055840-A1 | COMPOSITIONS FOR DYEING KERATIN-CONTAINING FIBERS | KRT18, JUP, CKAP4 | TDP1 2258/4885LMNA 278/4885ALDH1A1 1527/4885 |
| US-20110206627-A1 | O/W Emulsified Composition | CCNE2, CCNO, CCNB1 | TDP1 2699/4885LMNA 433/4885ALDH1A1 2756/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | TDP1 3009/4885LMNA 4810/4885ALDH1A1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.